Indication: Olanzapine is indicated for the treatment of schizophrenia. It is effective in maintaining clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of a moderate to severe manic episode. In bipolar patients with a manic episode that has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence.
Brand name: Zyprexa.
Regulatory status: Registered in October 2003 in the EU for the prevention of recurrence of bipolar disorder. Registered in June 2002 in the EU for manic episodes associated with bipolar disorder.
Launch date: Not available.